In conversations about type 2 diabetes, Jardiance often comes up alongside GLP-1 medications. Because both are used to manage blood sugar, many patients assume they are interchangeable, or that Jardiance is simply a pill version of a GLP-1. That assumption is understandable, but it is not accurate.
This article goes beyond a one-line fact check. It explains the physiological reason the two drug classes differ: how each works, how Jardiance’s FDA-approved uses have grown since 2014, and why its effect on weight is often misunderstood. It closes with why choosing a drug class is a clinical decision rather than a matter of name recognition.
The Quick Answer: Jardiance Is Not a GLP-1 Medication
Jardiance (empagliflozin) is not a GLP-1 medication. It belongs to a separate drug class called SGLT2 inhibitors.
The official FDA prescribing information states this directly: JARDIANCE tablets for oral use contain empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2). This is a formal classification:
- ATC classification code: A10BK03 (per the European Medicines Agency)
- Pharmacologic labels: anti-diabetic, hypoglycemic, SGLT2 inhibitor, gliflozin
The confusion likely comes from a shared goal. Both SGLT2 inhibitors and GLP-1 medications lower blood sugar in type 2 diabetes. A shared goal, however, does not mean a shared mechanism.
What Actually Defines a GLP-1 Medication
GLP-1 receptor agonists act mainly on the pancreas and gastrointestinal tract. In general terms, medications in this class:
- Stimulate insulin release when blood sugar is elevated
- Reduce glucagon secretion, a hormone that raises blood sugar
- Slow gastric emptying
- Promote a sense of fullness, or satiety
Examples include liraglutide, exenatide, dulaglutide, and lixisenatide. Most GLP-1 medications are given by injection, a practical difference from Jardiance that matters for many patients.
How Jardiance Actually Works: The SGLT2 Mechanism
Jardiance works in the kidneys. As the kidneys filter blood, SGLT2 is the main transporter that reabsorbs glucose from the filtered fluid and returns it to circulation.
Empagliflozin blocks this transporter. Less glucose is reabsorbed, more passes into the urine, and blood glucose levels fall. The European Medicines Agency describes it in plain terms: by blocking SGLT2, empagliflozin causes the kidneys to pass more glucose into the urine, reducing glucose levels in the blood.
Empagliflozin is also notably precise. A peer-reviewed pharmacology review published in ScienceDirect describes it as having the highest SGLT2 specificity among clinically used or tested SGLT2 inhibitors. Insulin release and digestion are not its primary targets.
Same Blood-Sugar Goal, Two Different Pathways: A Side-by-Side Comparison
| Feature | SGLT2 Inhibitors (e.g., Jardiance) | GLP-1 Receptor Agonists |
|---|---|---|
| Primary site of action | Kidneys | Pancreas and GI tract |
| How blood sugar falls | More glucose excreted in urine | Hormonal signaling: more insulin, less glucagon, slower digestion |
| Dosage form | Oral pill, once daily | Mostly injectable |
| General GI side effects | Fewer | More common |
| Effect on appetite | Not a primary effect | Promotes satiety |
Both classes lower blood sugar, but through entirely separate biological routes. That is the core distinction.
From Diabetes Drug to Cardiorenal Protector: Jardiance’s Expanding FDA Approval History
Jardiance’s clinical role has grown considerably, which explains why some patients are prescribed it for reasons beyond blood sugar.
- 2014: FDA approval as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
- 2016: Approval to lower the risk of cardiovascular death in adults with type 2 diabetes and established heart disease.
- 2021 to 2022: Approval to reduce cardiovascular death and hospitalization in adults with heart failure, eventually regardless of ejection fraction and with or without diabetes.
- 2023: Approval to lower the risk of worsening kidney function, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
The kidney indication was supported by the EMPA-KIDNEY trial, in which empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% compared with placebo.
Today, Jardiance carries four FDA-approved uses spanning diabetes, cardiovascular risk, heart failure, and chronic kidney disease.
The Weight-Loss Misconception: Why Jardiance Isn’t a GLP-1 Alternative
Because some patients lose weight on Jardiance, it is sometimes assumed to be a milder or oral substitute for a GLP-1 medication. That assumption is incorrect, and it is not how Jardiance is indicated or intended to be used.
Jardiance is not FDA-approved for weight loss. Any weight change is a secondary effect of its glucose-excretion mechanism. Research suggests that glucose lost through urine accounts for roughly 240 to 400 calories per day, and studies show weight loss of about 3% of starting body weight. That effect comes from lost calories, not appetite regulation, and it is substantially smaller than what is generally associated with GLP-1 medications for weight loss.
When Jardiance and a GLP-1 Medication Are Used Together
In clinical practice, the two classes are often combined rather than substituted. For example, if GLP-1 therapy alone has not brought a patient to a target A1C level, a prescriber may consider adding an SGLT2 inhibitor such as Jardiance.
This reflects the complementary nature of the mechanisms: one works through the kidneys, while the other works through hormonal signaling in the pancreas and gut. Whether such a combination is appropriate is always an individual clinical judgment.
Other Medications in Each Drug Class
SGLT2 inhibitors (Jardiance’s class):
- Empagliflozin (Jardiance)
- Dapagliflozin
- Canagliflozin
GLP-1 receptor agonists (a separate class):
- Liraglutide
- Exenatide
- Dulaglutide
- Lixisenatide
- Additional agents in development
Each class has its own distinct family of medications.
Why the Right Drug Class Depends on Clinical Evaluation, Not Guesswork
Knowing which drug class fits a patient is not about recognizing a name from a friend’s prescription or a headline. It depends on kidney function, cardiovascular risk, metabolic profile, other medications, and long-term goals.
Medication is also only one tool. At Red Mountain, medication is treated as foundation-stage support within a broader plan that includes metabolic assessment, labs, nutrition strategy, and ongoing monitoring. Drawing on more than 30 years of real-world patient outcomes and in-person evaluation at brick-and-mortar clinics, Red Mountain’s providers assess whether an SGLT2 inhibitor, a GLP-1 medication, a compounded GLP-1 medication, or another approach fits a patient’s metabolic picture.
That evaluation-first process is what separates clinical guidance from self-diagnosing based on a drug name alone.
Conclusion: Two Classes, Two Mechanisms, One Clinical Decision
Jardiance is an SGLT2 inhibitor that works through the kidneys, not a GLP-1 medication that works through the pancreas and gut, even though both help manage blood sugar in type 2 diabetes. Since its 2014 diabetes approval, Jardiance has added indications for cardiovascular risk, heart failure, and chronic kidney disease, giving it a distinct clinical identity.
Its modest weight effect is a byproduct of its mechanism, not a reason to choose it over a GLP-1 medication for weight management. The right medication class is a clinical decision shaped by a patient’s full health picture.
Next Step: Understanding Your Own Metabolic Picture
Understanding which medication class (an SGLT2 inhibitor, a GLP-1 medication, or another option) fits an individual’s health profile is exactly what a clinical consultation is designed to clarify. A consult is a starting point for answers, not a commitment to any specific medication or program.
Red Mountain’s approach is built on decades of clinical experience, in-person providers, and long-term support from foundation through maintenance. For anyone unsure how their prescription fits their broader metabolic health, a conversation with a provider is usually the next step.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
